de Melo T S, Lima P R, Carvalho K M M B, Fontenele T M, Solon F R N, Tomé A R, de Lemos T L G, da Cruz Fonseca S G, Santos F A, Rao V S, de Queiroz M G R
Faculdade de Farmácia, Universidade Federal do Ceará, Fortaleza, CE, Brasil.
Laboratório de Produtos Naturais, Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, CE, Brasil.
Braz J Med Biol Res. 2017 Jan 5;50(1):e5630. doi: 10.1590/1414-431X20165630.
Previous studies have reported on the glucose and lipid-lowering effects of ferulic acid (FA) but its anti-obesity potential has not yet been firmly established. This study investigated the possible anti-obesitogenic effects of FA in mice fed a high-fat diet (HFD) for 15 weeks. To assess the antiobesity potential of FA, 32 male Swiss mice, weighing 20-25 g (n=6-8 per group) were fed a normal diet (ND) or HFD, treated orally or not with either FA (10 mg/kg) or sibutramine (10 mg/kg) for 15 weeks and at the end of this period, the body weights of animals, visceral fat accumulation, plasma levels of glucose and insulin hormone, amylase and lipase activities, the satiety hormones ghrelin and leptin, and tumor necrosis factor-α (TNF-α) and monocyte chemoattractant protein-1 (MCH-1) were analyzed. Results revealed that FA could effectively suppress the HFD-associated increase in visceral fat accumulation, adipocyte size and body weight gain, similar to sibutramine, the positive control. FA also significantly (P<0.05) decreased the HFD-induced elevations in serum lipid profiles, amylase and lipase activities, and the levels of blood glucose and insulin hormone. The markedly elevated leptin and decreased ghrelin levels seen in HFD-fed control mice were significantly (P<0.05) reversed by FA treatment, almost reaching the values seen in ND-fed mice. Furthermore, FA demonstrated significant (P<0.05) inhibition of serum levels of inflammatory mediators TNF-α, and MCH-1. These results suggest that FA could be beneficial in lowering the risk of HFD-induced obesity via modulation of enzymatic, hormonal and inflammatory responses.
以往的研究报道了阿魏酸（FA）的降血糖和降血脂作用，但其抗肥胖潜力尚未得到确切证实。本研究调查了FA对高脂饮食（HFD）喂养15周小鼠可能的抗肥胖作用。为了评估FA的抗肥胖潜力，将32只体重20 - 25 g的雄性瑞士小鼠（每组n = 6 - 8只）分为正常饮食（ND）组或HFD组，口服或不口服FA（10 mg/kg）或西布曲明（10 mg/kg），持续15周。在此期间结束时，分析动物的体重、内脏脂肪堆积、血浆葡萄糖和胰岛素激素水平、淀粉酶和脂肪酶活性、饱腹感激素胃饥饿素和瘦素，以及肿瘤坏死因子-α（TNF-α）和单核细胞趋化蛋白-1（MCH-1）。结果显示，与阳性对照西布曲明相似，FA能有效抑制HFD相关的内脏脂肪堆积、脂肪细胞大小增加和体重增加。FA还显著（P<0.05）降低了HFD诱导的血清脂质谱、淀粉酶和脂肪酶活性以及血糖和胰岛素激素水平的升高。FA治疗显著（P<0.05）逆转了HFD喂养的对照小鼠中明显升高的瘦素水平和降低的胃饥饿素水平，几乎达到ND喂养小鼠的水平。此外，FA对炎症介质TNF-α和MCH-1的血清水平有显著（P<0.05）抑制作用。这些结果表明，FA可能通过调节酶、激素和炎症反应，有助于降低HFD诱导的肥胖风险。
